GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annovis Bio Inc (FRA:07X) » Definitions » Additional Paid-In Capital

Annovis Bio (FRA:07X) Additional Paid-In Capital : €99.33 Mil(As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Annovis Bio Additional Paid-In Capital?


Annovis Bio's quarterly additional paid-in capital increased from Sep. 2023 (€88.74 Mil) to Dec. 2023 (€94.00 Mil) and increased from Dec. 2023 (€94.00 Mil) to Mar. 2024 (€99.33 Mil).

Annovis Bio's annual additional paid-in capital increased from Dec. 2021 (€64.80 Mil) to Dec. 2022 (€77.76 Mil) and increased from Dec. 2022 (€77.76 Mil) to Dec. 2023 (€94.00 Mil).


Annovis Bio Additional Paid-In Capital Historical Data

The historical data trend for Annovis Bio's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annovis Bio Additional Paid-In Capital Chart

Annovis Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial 0.18 17.90 64.80 77.76 94.00

Annovis Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 78.39 86.83 88.74 94.00 99.33

Annovis Bio Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Annovis Bio Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Annovis Bio's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Annovis Bio (FRA:07X) Business Description

Traded in Other Exchanges
Address
1055 Westlakes Drive, Suite 300, Berwyn, PA, USA, 19312
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301.

Annovis Bio (FRA:07X) Headlines

No Headlines